Bacillus coagulans (Heyndrickxia coagulans)
Also called: Heyndrickxia coagulans, Weizmannia coagulans, B. coagulans, Bacillus coagulans GBI-30, 6086, Bacillus coagulans Unique IS2, Bacillus coagulans MTCC 5856
Bacillus coagulans, also named Weizmannia coagulans and, after a 2023 proposal, Heyndrickxia coagulans, is a spore-forming, lactic acid-producing bacterium. Products contain specific strains, such as GBI-30, 6086, Unique IS2 and MTCC 5856; results here are reported strain by strain.
- Category
- Probiotic
- Forms
- Bacterial spore preparations; amounts stated in CFU or spores
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-30
Class 2 Moderately studied in people. Evidence is strain-specific, so trials are counted per strain. We confirmed 10 placebo-controlled RCTs of single strains: Unique IS2 (3), GBI-30, 6086 (3), MTCC 5856 (2) and LBSC (2). No strain has 10 RCTs or a review pooling 5 or more. [4]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BStomach and gut5 topics
- BIrritable bowel syndrome in adults (strain Unique IS2)
- BIrritable bowel syndrome in children aged 4–12 (strain Unique IS2)
- CStool frequency in adults with chronic constipation (strain Unique IS2)
- CFunctional gastrointestinal complaints in healthy adults (strain GBI-30, 6086)
- CFunctional gas and bloating (strain MTCC 5856)
CBones and joints1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Irritable bowel syndrome in adults (strain Unique IS2) | B | In an RCT of 136 adults with IBS, Unique IS2 (2 billion CFU/day for 8 weeks) improved abdominal pain/discomfort and complete spontaneous bowel movements versus placebo. [4] |
| Irritable bowel syndrome in children aged 4–12 (strain Unique IS2) | B | In a double-blind RCT of 141 children, 8 weeks of Unique IS2 chewable tablets reduced pain intensity and improved stool consistency, bloating and other IBS symptoms versus placebo. [5] |
| Stool frequency in adults with chronic constipation (strain Unique IS2) | C | A 2022 meta-analysis of constipation RCTs found probiotics overall increased stool frequency, but the Bacillus coagulans Unique IS2 subgroup did not show a significant effect. [6] |
| Functional gastrointestinal complaints in healthy adults (strain GBI-30, 6086) | C | In a double-blind RCT of 111 adults in China, GBI-30, 6086 (1 x 10^9/day for 4 weeks) increased stools per week and improved fecal consistency versus placebo, with fewer participants constipated. [7] |
| Functional gas and bloating (strain MTCC 5856) | C | In a double-blind RCT of 70 adults in India, MTCC 5856 (2 billion spores/day for 4 weeks) lowered indigestion (gas and bloating) scores versus placebo. [8] |
| Rheumatoid arthritis, alongside standard medication (strain GBI-30, 6086) | C | In a pilot RCT of 45 adults, 60 days of GBI-30, 6086 gave a borderline improvement in patient pain assessment (P = .052) and a significant pain-scale improvement versus placebo; authors call for larger trials. [10] |
Main constituents: Heyndrickxia coagulans (formerly Bacillus coagulans): spore-forming, lactic acid-producing bacterium [1]; Weizmannia coagulans is a synonym of Bacillus coagulans [3]; A 2023 genome-based study proposed transferring the genus Weizmannia to Heyndrickxia [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Unique IS2, adult IBS trial: 2 billion CFU/day for 8 weeks. [4]
- GBI-30, 6086, healthy-adult trial: 1 x 10^9/day for 4 weeks. [7]
- MTCC 5856, diarrhea-predominant IBS pilot trial: 2 x 10^9 CFU/day for 90 days alongside standard care. [9]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- In the 2026 IBS meta-analysis, adverse-effect rates with Unique IS2 and with MTCC 5856 did not differ significantly from placebo. [15]
- In the 136-adult Unique IS2 trial, hematology remained normal and no severe adverse events were reported. [4]
- In the 36-patient MTCC 5856 trial, laboratory parameters and vital signs stayed within the normal range over 90 days. [9]
- FDA (2023, probiotics in general): administering probiotics to preterm infants may cause infection or invasive and potentially fatal disease; FDA reported one infant death and more than two dozen other adverse events. [16]
- ODS (probiotics in general): probiotics may cause harm in certain populations, including people who are severely ill or immunocompromised. [16]
Identity, quality and standardization
Regulatory status
- Canada: Bacillus coagulans is listed in Appendix I (Table 6) of Health Canada's probiotics monograph (April 24, 2026) as excluded from the monograph and its compendial application process. [17]
- US: No NDI notification naming Bacillus coagulans, Weizmannia coagulans or Heyndrickxia coagulans was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [18]
- US: FDA's GRAS Notice Inventory lists GRN 399 (GBI-30, 6086 spores; closed July 31, 2012) for use in a wide range of conventional foods, with the response 'FDA has no questions'. [19]
- US: GRN 526 (Unique IS2 spores; closed March 23, 2015) for conventional foods also received 'FDA has no questions'. [20]
- US: GRN 601 (MTCC 5856 spores; closed April 28, 2016) for conventional foods also received 'FDA has no questions'. [21]
- EU: EFSA (2022) states that a Weizmannia coagulans production strain qualifies for the qualified presumption of safety (QPS) approach (feed-additive opinion). [3]
- US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed; a firm is responsible for ensuring its products are not adulterated. [22]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Spores of named Bacillus (Heyndrickxia) coagulans strains, e.g. GBI-30, 6086, Unique IS2, MTCC 5856 Spore-forming, lactic acid-producing bacterium [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming Bacillus coagulans, Weizmannia coagulans or Heyndrickxia coagulans was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
- FDA's GRAS Notice Inventory lists strain-specific spore preparations for conventional foods with the response 'FDA has no questions', including GRN 399 (GBI-30, 6086; 2012), GRN 526 (Unique IS2; 2015) and GRN 601 (MTCC 5856; 2016). [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of Bacillus coagulans (Heyndrickxia coagulans) was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-30). [P4]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P6]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Cirio S, et al. Oral health benefits of Heyndrickxia coagulans: a systematic review and meta-analysis of current evidence. Front Oral Health 2026;6:1733955 (PMID 41641154), 2026-01-20. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- FDA. GRAS Notice Inventory: GRN No. 399, Preparation of Bacillus coagulans strain GBI-30, 6086 spores (date of closure Jul 31, 2012), 2012-07-31. hfpappexternal.fda.gov
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-30), 2026-10-30. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
Sources
- Cirio S, et al. Oral health benefits of Heyndrickxia coagulans: a systematic review and meta-analysis of current evidence. Front Oral Health 2026;6:1733955 (PMID 41641154), 2026-01-20. pubmed.ncbi.nlm.nih.gov
- Narsing Rao MP, et al. Genome-based reclassification of Bacillus acidicola, Bacillus pervagus and the genera Heyndrickxia, Margalitia and Weizmannia. Int J Syst Evol Microbiol 2023;73(7) (PMID 37462355), 2023-07. pubmed.ncbi.nlm.nih.gov
- EFSA FEEDAP Panel. Safety and efficacy of a feed additive consisting of lactic acid produced by Weizmannia coagulans (synonym Bacillus coagulans) DSM 32789 for all animal species except for fish. EFSA J 2022;20(4):e07268 (PMID 35505780), 2022-04-29. pubmed.ncbi.nlm.nih.gov
- Madempudi RS, et al. Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults. Sci Rep 2019;9(1):12210 (PMID 31434935), 2019-08-21. pubmed.ncbi.nlm.nih.gov
- Sudha MR, et al. Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study. Benef Microbes 2018;9(4):563-572 (PMID 29695183), 2018-06-15. pubmed.ncbi.nlm.nih.gov
- van der Schoot A, et al. Probiotics and synbiotics in chronic constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr 2022;41(12):2759-2777 (PMID 36372047), 2022-12. pubmed.ncbi.nlm.nih.gov
- Gang H, et al. Impact of Heyndrickxia (Bacillus) coagulans GBI-30, 6086 (BC30) probiotic on gastrointestinal function in healthy adults: a randomised controlled trial. Benef Microbes 2025;17(1):29-46 (PMID 40707016), 2025-07-22. pubmed.ncbi.nlm.nih.gov
- Majeed M, et al. The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: a randomized, double-blind, placebo-controlled study. Medicine (Baltimore) 2023;102(9):e33109 (PMID 36862903), 2023-03-03. pubmed.ncbi.nlm.nih.gov
- Majeed M, et al. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant irritable bowel syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J 2016;15:21 (PMID 26922379), 2016-02-27. pubmed.ncbi.nlm.nih.gov
- Mandel DR, Eichas K, Holmes J. Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med 2010;10:1 (PMID 20067641), 2010-01-12. pubmed.ncbi.nlm.nih.gov
- Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med 2009;121(2):119-24 (PMID 19332970), 2009-03. pubmed.ncbi.nlm.nih.gov
- LeMoire A, et al. Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial. Benef Microbes 2025;16(5):533-543 (PMID 40456531), 2025-06-01. pubmed.ncbi.nlm.nih.gov
- Maity C, Gupta AK. A prospective, interventional, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Bacillus coagulans LBSC in the treatment of acute diarrhea with abdominal discomfort. Eur J Clin Pharmacol 2019;75(1):21-31 (PMID 30264164), 2019-01. pubmed.ncbi.nlm.nih.gov
- Gupta AK, Maity C. Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: a prospective, interventional, randomized, double-blind, placebo-controlled clinical study. Medicine (Baltimore) 2021;100(3):e23641 (PMID 33545934), 2021-01-22. pubmed.ncbi.nlm.nih.gov
- Maslennikov R, et al. Strain-specific systematic review with meta-analysis of probiotics efficacy in the treatment of irritable bowel syndrome. J Clin Med 2026;15(3):1152 (PMID 41682832; full text PMC12898053), 2026-02-02. pmc.ncbi.nlm.nih.gov
- NIH Office of Dietary Supplements. Probiotics: Fact Sheet for Health Professionals (Updated March 25, 2025), 2025-03-25. ods.od.nih.gov
- Health Canada, NNHPD. Natural health product monograph: Probiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- FDA. GRAS Notice Inventory: GRN No. 399, Preparation of Bacillus coagulans strain GBI-30, 6086 spores (date of closure Jul 31, 2012), 2012-07-31. hfpappexternal.fda.gov
- FDA. GRAS Notice Inventory: GRN No. 526, Bacillus coagulans strain Unique IS2 spores preparation (date of closure Mar 23, 2015), 2015-03-23. hfpappexternal.fda.gov
- FDA. GRAS Notice Inventory: GRN No. 601, Preparation of Bacillus coagulans strain MTCC 5856 spores (date of closure Apr 28, 2016), 2016-04-28. hfpappexternal.fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in probiotic: Akkermansia muciniphila (pasteurized) · Bifidobacterium animalis subsp. lactis BB-12 · Escherichia coli Nissle 1917 (EcN) · Lacticaseibacillus paracasei strain Shirota (LcS) · Lacticaseibacillus rhamnosus GG (LGG) · Lactiplantibacillus plantarum 299v · Limosilactobacillus reuteri DSM 17938 · Probiotics · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.